Adam M. Spivak
( out of 44 reviews )

Adam M. Spivak, MD, FACP

Languages spoken: English
Schedule an Appointment

Clinical Locations

University of Utah Hospital

801-581-2121

  • Dr. Spivak joined the faculty of the University of Utah Department of Internal Medicine (Division of Infectious Diseases) in the fall of 2011 after completing residency and fellowship training at Johns Hopkins Hospital in Baltimore, Maryland. He cares for people living with HIV infection as a member of the Infectious Diseases Clinic and attends on the inpatient Infectious Diseases consult service at the University of Utah Hospital. Dr. Spivak teaches in the medical school, mentors post-graduate trainees, conducts translational research on HIV persistence and eradication, and is a co-founder and leader of Utah's first and only free HIV prevention clinic. He is a scientific member of the NIH AIDS Clinical Trial Group and an investigator in the NIH RECOVER cohort studying post-acute symptoms of COVID-19 infection.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Infectious Disease)

    Patient Rating

    4.9 /5
    ( out of 44 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 03, 2023

    Dr. Spivak is both knowledgeable and caring. I always have a lot of questions when it comes to my health and he takes the time to listen and answer them in a way I understand. He is easy to talk to about sensitive topics and truly cares.

    July 14, 2023

    Great bedside manner, very thorough and listens to my concerns. He is very accommodating and also promptly answer my messages instead of his assistant. He also spend his time explaining things and his team are professionals yet very kind. I would recommend him a 100%.

    June 03, 2023

    Dr. Spivak just makes me feel at ease and seems to be happy that he is there. I'm always the last patient of the day, but Adam is never in a hurry or appears to be rushing.

    See More Patient Comments

  • Dr. Spivak joined the faculty of the University of Utah Department of Internal Medicine (Division of Infectious Diseases) in the fall of 2011 after completing residency and fellowship training at Johns Hopkins Hospital in Baltimore, Maryland. He cares for people living with HIV infection as a member of the Infectious Diseases Clinic and attends on the inpatient Infectious Diseases consult service at the University of Utah Hospital. Dr. Spivak teaches in the medical school, mentors post-graduate trainees, conducts translational research on HIV persistence and eradication, and is a co-founder and leader of Utah's first and only free HIV prevention clinic. He is a scientific member of the NIH AIDS Clinical Trial Group and an investigator in the NIH RECOVER cohort studying post-acute symptoms of COVID-19 infection.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Pathology -Adjunct
    Academic Divisions
    Infectious Diseases
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Infectious Disease)

    Education history

    Fellowship Infectious Diseases - Johns Hopkins University School of Medicine Fellow
    Internal Medicine - Johns Hopkins University School of Medicine Chief Resident
    Residency Internal Medicine - Johns Hopkins University School of Medicine Resident
    Internal Medicine - Johns Hopkins University School of Medicine Intern
    Professional Medical Medicine - University of Maryland School of Medicine M.D.
    English Literature - Princeton University A.B.

    Selected Publications

    Journal Article

    1. Larragoite ET, Nell RA, Martins LJ, Barrows LR, Planelles V, Spivak AM (2021). Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation. Biochem Pharmacol, 195, 114844.
    2. Redecke V, Tawaratsumida K, Larragoite ET, Williams ESCP, Planelles V, Spivak AM, Hirayama L, Elgort M, Swenson S, Smith R, Worthen B, Zimmerman R, Slev P, Cahoon B, Astill M, Hcker H (2021). A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation. Sci Rep, 11(1), 24507.
    3. Innis EA, Levinger C, Szaniawski MA, Williams ESCP, Alcam J, Bosque A, Schiffer JT, Coiras M, Spivak AM, Planelles V (2021). Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence. Biochem Pharmacol, 194, 114816.
    4. Tsai YC, Nell RA, Buckendorf JE, Ksz N, Mwangi PW, Berkecz R, Rdei D, Vasas A, Spivak AM, Hohmann J (2021). Bioactive Compounds from Euphorbia usambarica Pax. with HIV-1 Latency Reversal Activity. Pharmaceuticals (Basel), 14(7).
    5. Sarabia I, Novis CL, Macedo AB, Takata H, Nell R, Kakazu JC, Furler RL, Shakya B, Schubert HL, Hill CP, DePaula-Silva AB, Spivak AM, Trautmann L, Planelles V, Bosque A (2021). Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS. Front Immunol, 12, 682182.
    6. Trivedi S, Afroz T, Bennett MS, Angell K, Barros F, Nell RA, Ying J, Spivak AM, Leung DT (2021). Diverse Mucosal-Associated Invariant TCR Usage in HIV Infection. Immunohorizons, 5(5), 360-369.
    7. Gibson EG, Pender M, Angerbauer M, Cook C, Jones B, Spivak AM, Spivak ES, Swaminathan S (2021). Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis. Open Forum Infect Dis, 8(7), ofab176.
    8. Zheng Y, Larragoite ET, Williams ESCP, Lama J, Cisneros I, Delgado JC, Slev P, Rychert J, Innis EA, Coiras M, Rondina MT, Spivak AM, Planelles V (2021). Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. Virol J, 18(1), 1.
    9. Schynkel T, Szaniawski MA, Spivak AM, Bosque A, Planelles V, Vandekerckhove L, Trypsteen W (2020). Interferon-Mediated Long Non-Coding RNA Response in Macrophages in the Context of HIV. Int J Mol Sci, 21(20).
    10. Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic D (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv, 4(19), 4864-4868.
    11. Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, Chomont N, Bar KJ, Yu XG, Lichterfeld M, Alcami J, Hazuda D, Bushman F, Siliciano JD, Betts MR, Spivak AM, Planelles V, Hahn BH, Smith DM, Ho YC, Buzon MJ, Gaebler C, Paiardini M, Li Q, Estes JD, Hope TJ, Kostman J, Mounzer K, Caskey M, Fox L, Frank I, Riley JL, Tebas P, Montaner LJ, BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection (2020). Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med, 26(9), 1339-1350.
    12. Sorensen ES, Macedo AB, Resop RS, Howard JN, Nell R, Sarabia I, Newman D, Ren Y, Jones RB, Planelles V, Spivak AM, Bosque A (2020). Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents. Antimicrob Agents Chemother, 64(8).
    13. Pache L, Marsden MD, Teriete P, Portillo AJ, Heimann D, Kim JT, Soliman MSA, Dimapasoc M, Carmona C, Celeridad M, Spivak AM, Planelles V, Cosford NDP, Zack JA, Chanda SK (2020). Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo. Cell Rep Med, 1(3), 100037.
    14. Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, Spivak AM, Alukal JP, Zhang X, Xiong C, Li PS, Hotaling JM (2020). No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril, 113(6), 1135-1139.
    15. Rodrguez-Mora S, Spivak AM, Szaniawski MA, Lpez-Huertas MR, Alcam J, Planelles V, Coiras M (2019). Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Curr HIV/AIDS Rep, 16(5), 414-422.
    16. Szaniawski MA, Spivak AM, Bosque A, Planelles V (2018). Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages. J Infect Dis, 219(5), 777-785.
    17. Reeves DB, Duke ER, Wagner TA, Palmer SE, Spivak AM, Schiffer JT (2018). A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun, 9(1), 4811.
    18. Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V (2018). Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. Antimicrob Agents Chemother, 62(11).
    19. Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A (2018). Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight, 3(19).
    20. Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A (2018). Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Res Hum Retroviruses, 34(9), 769-777.
    21. Szaniawski MA, Spivak AM, Cox JE, Catrow JL, Hanley T, Williams ESCP, Tremblay MJ, Bosque A, Planelles V (2018). SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition. mBio, 9(3).
    22. Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genesc M, Castellv J, Wu G, Del Rio Estrada PM, Gonzlez-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Tern G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ (2018). CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med, 10(437).
    23. Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V (2017). Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep, 18(5), 1324-1334.
    24. Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V (2016). Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology, 13(1), 88.
    25. Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM (2016). HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Front Immunol, 7, 356.
    26. Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V (2016). Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses, 32(2), 187-93.
    27. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V (2015). Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother, 59(10), 5984-91.
    28. Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, Knig R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK (2015). BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe, 18(3), 345-53.
    29. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG (2014). A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis, 58(6), 883-90.
    30. Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT (2013). Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A, 110(6), E448-57.
    31. Spivak AM, Salgado M, Rabi SA, OConnell KA, Blankson JN (2011). Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol, 85(19), 10399-403.
    32. Gaillard S, Dinoso JB, Marsh JA, DeZern AE, OConnell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN (2011). Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. J Clin Virol, 51(3), 195-8.
    33. Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF (2011). Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses, 27(7), 759-61.
    34. Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti D (2010). Spinal epidural abscess: current diagnosis and management. Curr Infect Dis Rep, 12(6), 484-91.
    35. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, OShea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F (2009). Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A, 106(23), 9403-8.

    Review

    1. Szaniawski MA, Spivak AM (2020). Senotherapeutics and HIV-1 Persistence. [Review]. Curr HIV/AIDS Rep, 17(3), 219-225.
    2. Szaniawski MA, Spivak AM (2019). Senotherapeutics for HIV and aging. [Review]. Curr Opin HIV AIDS, 15(2), 83-93.
    3. Spivak AM, Planelles V (2018). Novel Latency Reversal Agents for HIV-1 Cure. [Review]. Annu Rev Med, 69, 421-436.
    4. Spivak AM, Planelles V (2016). HIV-1 Eradication: Early Trials (and Tribulations). [Review]. Trends Mol Med, 22(1), 10-27.
    5. Barber AE, Norton JP, Spivak AM, Mulvey MA (2013). Urinary tract infections: current and emerging management strategies. [Review]. Clin Infect Dis, 57(5), 719-24.
    6. Spivak AM, Sydnor ER, Blankson JN, Gallant JE (2010). Seronegative HIV-1 infection: a review of the literature. [Review]. AIDS, 24(10), 1407-14.

    Book

    1. Spivak AM (2008). Harrison’s Principles of Internal Medicine Self-Assessment & Board Review. [contributing editor] (17th). New York, NY: McGraw Hill.

    Book Chapter

    1. Spivak A, Zaas A, Cheng A, Auwaerter P (2006). CNS Infections. In The Osler Medical Handbook (2nd, Chapter 57). Philadelphia, PA: Elsevier Mosby.
    2. Spivak A, Sosnay P, Cosgrove S (2006). Soft Tissue and Bone Infection. In The Osler Medical Handbook (2nd, Chapter 65). Philadelphia, PA: Elsevier Mosby.

    Commentary

    1. Larragoite ET, Spivak AM (2019). Down but not out. Elife, 8.

    Case Report

    1. Szaniawski MA, Spivak AM (2019). Recurrent Paenibacillus infection. Oxf Med Case Reports, 2019(5), omz034.
    2. Johnson RA, Spivak AM (2017). Lues Maligna. Open Forum Infect Dis, 4(3), ofx139.
    3. Rachakonda T, Kendall B, Spivak AM, Boltax J (2017). Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Open Forum Infect Dis, 4(3), ofx126.
    4. Spivak AM, Brennan TP, OConnell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson JN (2010). A case of seronegative HIV-1 infection. J Infect Dis, 201(3), 341-5.
    5. Vargas JD, Spivak AM (2009). A perfect storm. Gastric bezoar. Am J Med, 122(6), 519-21.
    6. Rodriguez ED, Bluebond-Langner R, Spivak AM, Eisig SB (2007). Surgical management of maxillofacial uremic osteodystrophy: a case report. J Oral Maxillofac Surg, 65(9), 1825-9.

    Letter

    1. Spivak AM, Siliciano RF (2010). Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk. [Letter to the editor]. AIDS, 24(10), 1603-4; author reply 1604.

  • Podcasts & News

    News

    The Scope Podcast